Strength-Endurance Circuit Training in Parkinson's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Strength-Endurance Training, Endurance Training.
- Who it may be relevant to
- Registry conditions: Parkinson Disease, Idiopathic. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Czechia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Strength-Endurance Circuit Training in Parkinson's Disease: Effects on Disease Severity, Physical Performance, Blood Biomarkers and Quality of Life.
Overview
The goal of this clinical trial is to determine whether adding strength training to aerobic training has a comparable or greater effect on the clinical status of Parkinson's disease patients than a standalone aerobic training. \- Does combined strength-endurance circuit training provide added benefits to physical performance, disease severity, blood biomarkers, and quality of life in PD patients compared to standalone aerobic training? Participants will: * undergo outcome measurements before and after the 12-week intervention and a 3-month follow-up measurement, * visit the clinic twice a week for 1-hour training sessions. * selected patients will be given a smartwatch with a pedometer that will count their average number of steps before, during and after the training period
Interventions
- Other Strength-Endurance Training
The intervention for the experimental Strength-Endurance group includes warm-up, three laps of strength and endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions. - Other Endurance Training
The intervention for the control Endurance training group includes warm-up, three laps of endurance exercises and cool-down. The training program lasts 3 months and includes two 1-hour training sessions per week, for a total of 24 sessions.
Primary outcome measures
- Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II. and III. [Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)]
Secondary outcome measures (8)
- One Repetition Maximum (1RM) [Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)]
- Timed Up and Go Test (TUG) [Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)]
- Blood irisin levels [Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)]
- Cardiopulmonary Exercise Testing [Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)]
- The Parkinson's Disease Questionnaire (PDQ-39) [Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)]
- Blood brain-derived neurotrophic factor levels [Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)]
- Blood cytokine levels [Time frame: From enrollment to the end of treatment at 12 weeks and 12 weeks after the end of treatment (Follow-up)]
- Average number of steps [Time frame: Average number of steps in the period before training (6 months), during the training period (3 months), period after training (3 months).]
Eligibility criteria
Inclusion criteria
- age ≥18 years
- diagnosis of idiopathic Parkinson´s disease
- Hoehn-Yahr Scale ≤ 2,5
- stable dopaminergic medication
Exclusion criteria
- age ≥75 years
- Hoehn-Yahr Scale ≥ 2,5
- deep brain stimulation
- presence of freezing
- Camptocormia
- inability to walk without support
- inability to perform study procedures
- limiting co-morbidities
- attendance at training sessions below 70%
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Czechia · 1 center
- Department of Neurology and Centre of Clinical Neuroscience First Faculty of Medicine, Cha — Prague
Publications
- Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, Rafferty MR, Kohrt WM, Comella CL. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013 Aug;28(9):1230-40. doi: 10.1002/mds.25380. Epub 2013 Mar 27. PMID 23536417
- Kam TI, Park H, Chou SC, Van Vranken JG, Mittenbuhler MJ, Kim H, A M, Choi YR, Biswas D, Wang J, Shin Y, Loder A, Karuppagounder SS, Wrann CD, Dawson VL, Spiegelman BM, Dawson TM. Amelioration of pathologic alpha-synuclein-induced Parkinson's disease by irisin. Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2204835119. doi: 10.1073/pnas.2204835119. Epub 2022 Aug 31. PMID 36044549
- Shi X, Gu Q, Fu C, Ma J, Li D, Zheng J, Chen S, She Z, Qi X, Li X, Wu S, Wang L. Relationship of irisin with disease severity and dopamine uptake in Parkinson's disease patients. Neuroimage Clin. 2024;41:103555. doi: 10.1016/j.nicl.2023.103555. Epub 2023 Dec 15. PMID 38134742
- Gamborg M, Hvid LG, Dalgas U, Langeskov-Christensen M. Parkinson's disease and intensive exercise therapy - An updated systematic review and meta-analysis. Acta Neurol Scand. 2022 May;145(5):504-528. doi: 10.1111/ane.13579. Epub 2022 Jan 8. PMID 34997759
Identifiers
NCT: NCT06893055 · 56125